Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hani Rjoob"'
Autor:
Hani Rjoob, Tayyab Khan
Publikováno v:
Bone Reports, Vol 14, Iss , Pp 100933- (2021)
Externí odkaz:
https://doaj.org/article/a569a7eef7ff49d0987df6bfdf5ad9b7
Autor:
Rachel L. McInnis, Hani Rjoob, Pavlo Ohorodnyk, John. Alexander Fraser, Stan H. M. Van Uum, Lulu L. C. D. Bursztyn
Publikováno v:
Journal of Neuro-Ophthalmology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad86f0bd5d9b14f1081dda6d935de13d
https://doi.org/10.1097/wno.0000000000001866
https://doi.org/10.1097/wno.0000000000001866
Autor:
Hani Rjoob, Stan VanUum, J Alexander Fraser, Pavalo Ohorodnyk, Lulu Bursztyn, Rachel Lang Mcinnis
Publikováno v:
Journal of the Endocrine Society. 6:A489-A490
Introduction Acromegaly is a chronic disorder characterized by excess growth hormone production, withclinical manifestations ranging from subtle signs to significant systemic complications. We describe a patient who presented with diplopia as initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27566cd175ea3183874bbeb9a3374700
https://doi.org/10.1210/jendso/bvac150.1016
https://doi.org/10.1210/jendso/bvac150.1016
Autor:
Hani Rjoob, Stephen E. Pautler, Anita Cave, Brendan Wallace, Stan Van Uum, Tayyab Khan, Dor Golomb
Publikováno v:
Videourology. 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::409e15ba04780e8dcf56c5e62a4e48eb
https://doi.org/10.1089/vid.2021.0040
https://doi.org/10.1089/vid.2021.0040
Autor:
Kristin K Clemens, Mayur Brahmania, Corrine Weernink, Khaled Lofty, Hani Rjoob, Amanda Berberich, Alan Gob
Publikováno v:
BMJ Open Quality. 11:e001796
BackgroundIn-hospital glycaemic management can reduce post-transplant morbidity, but is not always part of transplant care.ObjectiveWe aimed to reduce the mean number of postoperative days in hyperglycaemia (≥2 blood glucose >12 mmol/L in 24 hours)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e5e43901c6573f7cf522280d6ebf9b
https://doi.org/10.1136/bmjoq-2021-001796
https://doi.org/10.1136/bmjoq-2021-001796
Autor:
Tayyab Khan, Hani Rjoob
Publikováno v:
Journal of the Endocrine Society
Background: Immune checkpoint inhibitors are immunomodulatory antibodies directed against programmed cell death 1 (PD-1), Nivolumab, or cytotoxic T-lymphocyte antigen-4 (CTLA-4) Ipilimumab. They have improved outcomes in patients with advanced cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35ada0bedf01df3e12b4647de7f2b7d7
http://europepmc.org/articles/PMC8265911
http://europepmc.org/articles/PMC8265911